ArticleBMC medical genomics2025
First clinical report of a rare PDZD7 nonsense variant and recurrent mutations in Iranian families with autosomal recessive non-syndromic hearing loss.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular diagnosis of non-syndromic hearing loss in seven Iranian families using whole-exome sequencing.BMC medical genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHereditary hearing loss (HHL) is a genetically heterogeneous disorder, with autosomal recessive non-syndromic hearing loss (ARNSHL) comprising a significant proportion of cases globally. To investigate its genetic basis, we performed whole-exome sequencing (WES) in four consanguineous Iranian families affected by ARNSHL.
methodsWES was performed for the proband of each family using an Illumina platform. Secondary analysis was conducted with the DRAGEN Bio-IT Platform, and variant annotation was performed using wANNOVAR. Variants were prioritized based on inheritance patterns and bioinformatic predictions. Selected variants were validated by Sanger sequencing and assessed according to American College of Medical Genetics and Genomics / Association for Molecular Pathology (ACMG/AMP) guidelines.
resultsThrough this approach, we identified a previously reported missense variant in CDH23:c.5908G > A (p.Glu1970Lys), a nonsense variant in PDZD7:c.175 C > T (p.Arg59Ter) with no prior clinical report, and a recurrent nonsense variant in CDC14A:c.1126 C > T (p.Arg376Ter) in two families, providing further support as a founder mutation in Iran.
conclusionThese findings illustrate the potential diagnostic value of WES in ARNSHL and report, for the first time, a clinical association of the PDZD7 variant (c.175 C > T) with hearing loss. Pathogenic variants in CDH23 and CDC14A are consistent with their established involvement in HHL. Overall, this study provides additional insights into the genetic landscape and genotype–phenotype correlations in ARNSHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.